A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.
Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M.
Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152. [Epub ahead of print]
Kommentar schreiben
Di
11
Okt
2022
Sailing Croatia 2022
Fr
18
Jun
2021
Sailing trip Italy Greece
16
Apr
Sa
24
2020
01
Sep
7 weeks sailing in Croatia
23
Mai
Thanks to Saskia and Patrick for these recordings
Kommentar schreiben